To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

NCT07447986 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: SG301 SC Injection
DRUG: SG301 SC Injection
DRUG: SG301 SC placebo

Sponsor

Hangzhou Sumgen Biotech Co., Ltd.